Therapeutic IVT RNA
VectorBuilder offers a comprehensive platform for the development of RNA therapeutics including vaccines, chimeric antigen receptor (CAR), and gene editing therapies. Leveraging our extensive design and production experience for premade and custom RNAs, our team can support in vitro transcription (IVT) RNA and lipid nanoparticle (LNP) production for a variety of RNA-based expression systems. Researchers can further utilize our RNA development and LNP engineering services from candidate screening to functional testing to accelerate their therapeutic pipeline.
Highlights
Comprehensive Platform Offering research and clinical grades of RNA in a variety of systems, customizable IVT RNA production and LNP encapsulation, and a full suite of CRO and CDMO services.
Experts in RNA Development Team of scientists with expertise in the full scope of considerations for therapeutic IVT vector design, sequence optimization and screening, and process development.
Highest Quality and Consistency State-of-the-art facilities and equipment providing the highest quality and confidence for your final product, backed by a full panel of quality control assays.R&D Solutions
Therapeutic Solutions
Resources
Documents
Brochures & Flyers
Certificate of Analysis (COA)
Material Safety Data Sheet (MSDS)
Featured Citations
Phase Separation Enhanced PROTAC for Highly Efficient Protein Degradation
Yu, et al.
Biomacromolecules, 2024, doi: 10.1021/acs.biomac.4c00424
Products used:
Abstract: Biomacromolecular condensates formed via phase separation establish compartments for the enrichment of specific compositions, which is also used as a biological tool to enhance molecule condensation, thereby increasing the efficiency of biological processes. Proteolysis-targeting chimeras (PROTACs) have been developed as powerful tools for targeted protein degradation in cells, offering a promising approach for therapies for different diseases. Herein, we introduce an intrinsically disordered region in the PROTAC (denoted PSETAC), which led to the formation of droplets of target proteins in the cells and increased degradation efficiency compared with PROTAC without phase separation. Further, using a nucleus targeting intrinsically disordered domain, the PSETAC was able to target and degrade nuclear-located proteins. Finally, we demonstrated intracellular delivery of PSETAC using lipid nanoparticle-encapsulated mRNA (mRNA-LNP) for the degradation of the endogenous target protein. This study established the PSETAC mRNA-LNP method as a potentially translatable, safe therapeutic strategy for the development of clinical applications based on PROTAC.
>See more <Collapse 